Almustanyir, S., Alhabeeb, H
however, since then, four states (California, New Hampshire, Pennsylvania, and South Carolina) have eliminated coverage of GLP-1s for obesity treatment, likely reflecting recent state budget challenges and the significant costs associated with coverage
The series of reviews in Ryanodine Receptors: Structure, Function and Dysfunction in Clinical Disease will bring anyone rapidly up to speed in current progress in the field, as well as highlight remaining questions
Liraglutide Dictates Macrophage Phenotype in Apolipoprotein E Null Mice During Early Atherosclerosis
References Kovesdy CP
Once results are in, your provider will follow up to discuss your options, including GLP-1 medications if appropriate